LATEST UPDATES » Big Data, Bigger Disease Management and Current preparations to manage the Future Health of Singaporeans       » Big Data in Clinical Research Sector       » Professor Yuk-ling Yung receives Gerard P. Kuiper Prize       » AXA Assistance on Regenerative Medicine       » Singtel – Singapore Cancer Society Race against Cancer 2015       » Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death      
Clinipace Worldwide expands into Asia with acquisition of Choice Pharma
Clinipace Worldwide, a global digital contract research organization (dCRO) has closed its merger with Choice Pharma, a Pan-Asian contract research organization. Bringing these organizations together strengthens Clinipace Worldwide's operational and therapeutic expertise in Asia, a region in high demand by Clinipace's clients.

"With complementary operational strengths, a great reputation for quality and an experienced management team, the decision to combine the two companies was the best solution to continue to meet the long-term strategic goals of clients on both sides."

With the merger, the company extends its global footprint to include 20 operational offices in 15 countries, including new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.

"In order to continue to address the changing industry landscape and the high demand by clients for operations in Asia, we began the process of determining the best path for investing in the growth of our company, which led us to Choice Pharma," said Jeff Williams, CEO, Clinipace Worldwide. "With complementary operational strengths, a great reputation for quality and an experienced management team, the decision to combine the two companies was the best solution to continue to meet the long-term strategic goals of clients on both sides."

Williams continues, "With staff located in over 30 countries, Clinipace is the only purpose-built CRO with deep therapeutic expertise and broad geographic capacity built on our proprietary technology-enabled service model that we call a digital CRO, or dCRO. This model delivers visibility and simplified study management through real-time performance metrics at a reduced cost to venture-based, mid-tier life science firms around the world."

"A streamlined, efficient operational approach with real-time transparency that reduces cost and budget volatility is the future of clinical trials," said Chris Wang, Managing Director, Choice Pharma. "Not only can our clients leverage Clinipace's dCRO delivery model, but they now have access to a comprehensive and integrated clinical operations, data management, biostatistics, and regulatory consultancy outside of Asia."

The combined company creates a formidable global clinical development service offering for the mid-market, along with a world-class product development, regulatory, and GxP/CMC/QA consultancy. Most importantly, Clinipace and Choice clients now have access to new markets for site activation and patient enrollment. The 5th acquisition by Clinipace in recent years, the company is dedicated to building a new delivery model based on technological innovation, therapeutic expertise and global operations to support client needs.

Together, Clinipace Worldwide will now be home to over 640 global staff. The combined company has managed over 1,500 clinical research studies and 300+ completed regulatory and strategic development engagements.

Source: Business Wire

Click here for the complete issue.

news A Heroic Voyage — Sydney Brenner's Life in Science
news VeloX, A Minimally Invasive Prosthetic Heart Valve for treating Mitral Regurgitation
news Anti-CD25 monoclonal antibody (90Y-daclizumab) a favorable target towards systemic radio-immunotherapy in Hodgkin's Lymphoma

Credits to Sony Computer Entertainment and click here for behind the scenes.

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy